LINCOLN

Lincoln Pharmaceuticals Share Price

 

 

Invest in Lincoln Pharmaceuticals with 2.57X leverage

Invest with MTF
Lincoln Pharmaceuticals live price: ₹591.2. It opened at ₹591 vs previous close ₹587; intraday high/low: ₹607/₹586. The 50 & 200 DMA stand at ₹569.04/₹551.31.

Lincoln Pharmaceuticals Performance

  • Today's Low
  • ₹586
  • Today's High
  • ₹607
  • 52 Week Low
  • ₹440
  • 52 Week High
  • ₹677
  • Open Price₹591
  • Previous Close₹587
  • Volume24,035
  • 50 DMA₹569.04
  • 100 DMA₹548.33
  • 200 DMA₹551.31

Investment Returns

  • Over 1 Month -4.47%
  • Over 3 Month + 20.73%
  • Over 6 Month + 7.88%
  • Over 1 Year + 6%

Smart Investing Starts Here Start SIP with Lincoln Pharmaceuticals for Steady Growth!

Invest Now

Lincoln Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 13.5
  • PEG Ratio
  • -7.9
  • Market Cap Cr
  • 1,184
  • P/B Ratio
  • 1.6
  • Average True Range
  • 24.45
  • EPS
  • 43.85
  • Dividend Yield
  • 0.3
  • MACD Signal
  • 16.65
  • RSI
  • 48.01
  • MFI
  • 51.09

Lincoln Pharmaceuticals Financials

Lincoln Pharmaceuticals Technicals

EMA & SMA

Current Price
₹591.20
+ 4.35 (0.74%)
pointer
  • Bearish Moving Average 9
  • Bullish Moving Average 7
  • 20 Day
  • ₹599.17
  • 50 Day
  • ₹569.04
  • 100 Day
  • ₹548.33
  • 200 Day
  • ₹551.31

Resistance and Support

589.82 Pivot Speed
  • R3 616.23
  • R2 608.42
  • R1 597.63
  • S1 579.03
  • S2 571.22
  • S3 560.43

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Lincoln Pharmaceuticals manufactures pharmaceutical formulations across various therapeutic segments, including antibiotics, anti-malarial, and nutraceuticals. With state-of-the-art production facilities, it serves domestic and international markets, exporting products to over 60 countries globally.

Lincoln Pharmaceuticals has an operating revenue of Rs. 651.94 Cr. on a trailing 12-month basis. An annual revenue growth of 5% is not great, Pre-tax margin of 18% is great, ROE of 12% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is comfortably placed above its key moving averages, around 9% and 11% from 50DMA and 200DMA. From an O'Neil Methodology perspective, the stock has an EPS Rank of 64 which is a FAIR score but needs to improve its earnings, a RS Rating of 86 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at B which is evident from recent demand for the stock, Group Rank of 41 indicates it belongs to a fair industry group of Medical-Diversified and a Master Score of B is close to being the best. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Lincoln Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-02-12 Quarterly Results
2025-11-13 Quarterly Results
2025-08-07 Quarterly Results
2025-05-22 Audited Results & Final Dividend
2025-02-13 Quarterly Results
Date Purpose Remarks
2025-09-12 FINAL Rs.1.80 per share(18%)Final Dividend
View Lincoln Pharmaceuticals Dividend History Arrow

Lincoln Pharmaceuticals F&O

Lincoln Pharmaceuticals Shareholding Pattern

49.78%
0%
4.7%
36.28%
9.24%

Lincoln Pharmaceuticals FAQs

Lincoln Pharmaceuticals share price is ₹591 As on 24 March, 2026 | 16:26

The Market Cap of Lincoln Pharmaceuticals is ₹1184.2 Cr As on 24 March, 2026 | 16:26

The P/E ratio of Lincoln Pharmaceuticals is 13.5 As on 24 March, 2026 | 16:26

The PB ratio of Lincoln Pharmaceuticals is 1.6 As on 24 March, 2026 | 16:26

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23